Table 1: Clinical characteristics of the patients
Characteristic |
N = 127 |
Age, years, median (range) |
73 (48-89) |
Sex, male, n (%) |
61 (48%) |
Diabetes millitus, n (%) |
60 (48%) |
Alcohol, n (%) |
46 (37%) |
CEA, ng/ml, median (range) |
3.5 (0.5-39) |
CA19-9, U/ml, median (range) |
53 (1-11153) |
Operative procedures |
|
Pancreaticoduodenectomy |
64 (50%) |
Distal pancreatectomy |
60 (47%) |
Total pancreatectomy |
3 (2.4%) |
Stage, n% |
|
0 |
1 (0.7%) |
IA |
18 (14%) |
IB |
5 (4%) |
IIA |
43 (34%) |
IIB |
58 (46%) |
III |
1 (0.7%) |
IV |
1 (0.7%) |
Maximum tumor size, mm, median (range) |
24 (4-110) |
Histologial type |
|
Well differentiated type, n (%) |
49 (39%) |
Moderately differentiated type, n (%) |
56 (44%) |
Poorly differentiated type, n (%) |
11 (8.7%) |
Scirrhous type, n (%) |
0 |
Staging |
|
fCH (+), n (%) |
35 (28%) |
fDU (+), n (%) |
35 (28%) |
fS (+), n (%) |
44 (35%) |
fRP (+), n (%) |
74 (58%) |
fPV (+), n(%) |
23 (18%) |
fA (+), n(%) |
10 (8%) |
Lymph node metastasis (+), n (%) |
57 (45%) |
Adjuvant chemotherapy, n (%) |
72 (57%) |
GEM, n (%) |
25 (20%) |
GEM + S-1, n (%) |
1 (0.8%) |
nabPTX + GEM, n(%) |
1 (0.8%) |
S-1, n (%) |
45 (35%) |
Abbreviations: CEA: Carcinoembryonic Antigen; CA19-9: Carbohydrate Antigen 19-9; CH: Common Bile Duct Invasion; DU: Duodenal Invasion; S: anterior peripancreatic surface invasion; RP: Retroperipancreatic Margin; PV: Portal Vein Invasion; A: Arterial System Invasion; GEM: Gemcitabine; S-1: tegafur, gimestat, and otastat potassium combined drug; nabPTX: nab-paclitaxel